September 2024 - Portal Instruments welcomes Matt Regan to its Board of Directors. Regan has held extensive leadership roles for prominent pharmaceutical companies such as Abbvie, Novo Nordisk and Micreos.
Matt Regan, a seasoned leader in the healthcare and life sciences industry, has recently joined the Board of Directors at Portal Instruments. This strategic move brings valuable expertise to Portal, a company focused on revolutionizing drug delivery through its innovative needle-free injection technology.
Regan's addition to the board underscores Portal Instruments' commitment to innovation and growth. His pharmaceutical insights and leadership will play a crucial role in shaping the company's future as it continues to advance its technology.
May 10, 2022 - Portal Instruments has been featured in Fierce Pharma. "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
September 28, 2021 - Cambridge, MA Portal Instruments, developer of the PRIME needle-free drug delivery platform, announced that a new clinical study demonstrating patient preference for PRIME needle-free injections was published this month in the journal Drug Delivery.
May 9, 2022 - Gerresheimer AG, a leading provider of drug delivery systems, is expanding its portfolio of highly innovative platform technologies for drug delivery, today announcing an investment into US-based Portal Instruments.
Please fill out the details below and we will get back to you shortly.